Adverse events with IL‐17 and IL‐23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta‐analysis of phase III studies
Author:
Affiliation:
1. Department of Dermatology and Allergy Herlev and Gentofte Hospital University of Copenhagen Hellerup Denmark
2. Copenhagen Research Group for Inflammatory Skin Herlev and Gentofte Hospital Hellerup Denmark
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16073
Reference64 articles.
1. The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
2. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
3. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
4. Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
5. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
Cited by 68 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation;PLOS ONE;2024-08-09
2. Anti–Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency;New England Journal of Medicine;2024-07-11
3. Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis;Expert Opinion on Drug Safety;2024-04-23
4. Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab;Advances in Therapy;2024-03-05
5. Developmental drugs for sarcoidosis;Journal of Autoimmunity;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3